 | Up a level |
Journal Article
Asemissen, A. M., Scheid, C., Leypoldt, L., Schieferdecker, A., Besemer, B., Blau, I. -W., Goerner, M., Ko, Y. -D., Haenel, M., Duerig, J., Staib, P., Salwender, H., Mann, C., Munder, M., Graeven, U., Peceny, R., Lutz, R., Zago, M., Benner, A., Tichy, D., Bokemeyer, C., Goldschmidt, H. and Weisel, K. (2020). Mobilization of autologous stem cells under induction therapy with Isatuximab, Carfilzomib, Lenalidomide, Dexamethasone (Isa-KRd) in high risk myeloma patients: First results of the GMMG-CONCEPT trial. Oncol. Res. Treat., 43 (SUPPL 4). S. 94 - 96. BASEL: KARGER. ISSN 2296-5262
Baertsch, M., Wuchter, P., Schlenzka, J., Weisel, K., Noppeney, R., Martin, H., Lindemann, H., Haenel, M., Nogai, A., Scheid, C., Salwender, H., Fenk, R., Graeven, U., Reimer, P., Schmidt-Hieber, M., Goerner, M., Schmidt-Wolf, I., Klein, S., Ho, A. and Goldschmidt, H. (2015). EFFICIENCY AND TOXICITY OF CYCLOPHOSPHAMIDE BASED STEM CELL MOBILIZATION IN RELAPSED MULTIPLE MYELOMA PATIENTS: OBSERVATIONS FROM THE ONGOING PHASE III TRIAL RELAPSE. Haematologica, 100. S. 258 - 260. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Glossmann, J-P, Scheid, C., Engelhardt, M., Goldschmidt, H., Einsele, H., Starbatty, B., Bischoff, M., Follmann, M. and Skoetz, N. (2017). NEW CLINICAL PATHWAYS OF THE CENTERS OF EXCELLENCE NETWORK IN GERMANY: A NEW CONCEPT FOR STANDARDIZED CARE OF MULTIPLE MYELOMA PATIENTS. Haematologica, 102. S. 512 - 514. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Goldschmidt, H., Lokhorst, H. M., Mai, E. K., van der Holt, B., Blau, I. W., Zweegman, S., Weisel, K. C., Vellenga, E., Pfreundschuh, M., Kersten, M. J., Scheid, C., Croockewit, S., Raymakers, R., Hose, D., Potamianou, A., Jauch, A., Hillengass, J., Stevens-Kroef, M., Raab, M. S., Broijl, A., Lindemann, H. W., Bos, G. M. J., Brossart, P., Kooy, M. van Marwijk, Ypma, P., Duehrsen, U., Schaafsma, R. M., Bertsch, U., Hielscher, T., Jarari, Le, Salwender, H. J. and Sonneveld, P. (2018). Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMGHD-4 trial. Leukemia, 32 (2). S. 383 - 391. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Mai, E. K., Benner, A., Bertsch, U., Schmidt-Wolf, I. G. H., Haenel, A., Kunzmann, V, Naumann, R., Neben, K., Egerer, G., Hillengass, J., Neubauer, A., Peyn, A., Ko, Y-D, Peter, N., Salwender, H. J., Scheid, C. and Goldschmidt, H. (2015). Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in newly-diagnosed multiple myeloma: final results from the GMMG-HD2 trial. Oncol. Res. Treat., 38. S. 9 - 11. BASEL: KARGER. ISSN 2296-5262
Mai, E. K., Bertsch, U., Duerig, J., Kunz, C., Haenel, M., Blau, I. W., Munder, M., Jauch, A., Schurich, B., Hielscher, T., Merz, M., Huegle-Doerr, B., Seckinger, A., Hose, D., Hillengass, J., Raab, M. S., Neben, K., Lindemann, H-W, Zeis, M., Gerecke, C., Schmidt-Wolf, I. G. H., Weisel, K., Scheid, C., Salwender, H. and Goldschmidt, H. (2014). Bortezomib/cyclophosphamide/dexamethasone (VCD) is equally effective and has a favorable toxicity profile compared to bortezomib/doxorubicin/dexamethasone (PAd) as induction therapy in newly diagnosed, transplant-eligible myeloma patients: Results from the multicenter, phase III clinical trial GMMG-MM5. Oncol. Res. Treat., 37. S. 150 - 152. BASEL: KARGER. ISSN 2296-5262
Mai, E. K., Bertsch, U., Duerig, J., Kunz, C., Haenel, M., Blau, I. W., Munder, M., Jauch, A., Schurich, B., Hielscher, T., Merz, M., Huegle-Doerr, B., Seckinger, A., Hose, D., Hillengass, J., Raab, M. S., Neben, K., Lindemann, H-W, Zeis, M., Gerecke, C., Schmidt-Wolf, I. G. H., Weisel, K., Scheid, C., Salwender, H. and Goldschmidt, H. (2015). Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia, 29 (8). S. 1721 - 1730. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Mai, E. K., Hielscher, T., Bertsch, U., Schlenzka, J., Salwender, H. J., Munder, M., Gerecke, C., Pfreundschuh, M., Duehrsen, U., Brossart, P., Neben, K., Hillengass, J., Raab, M. S., Hose, D., Merz, M., Breitkreutz, I., Jauch, A., Martin, H., Lindemann, H. -W., Scheid, C., Weisel, K. C., Blau, I. W. and Goldschmidt, H. (2017). Prediction of early overall and infection-related mortality during induction therapy in transplant-eligible multiple myeloma - a pooled analysis from three GMMG phase III trials. Oncol. Res. Treat., 40. S. 36 - 38. BASEL: KARGER. ISSN 2296-5262
Merz, M., Hielscher, T., Seckinger, A., Jauch, A., Mai, E. K., Bertsch, U., Raab, M. S., Neben, K., Salwender, H., Blau, I. W., Lindemann, H. W., Duerig, J., Scheid, C., Haenel, M., Weisel, K., Delorme, S., Kauczor, H. U., Hose, D., Goldschmidt, H. and Hillengass, J. (2018). MAGNETIC RESONANCE IMAGING BEFORE AND AFTER UPFRONT AUTOLOGOUS TRANSPLANTATION IDENTIFIES PATIENTS WITH ADVERSE OUTCOME BUT RESPONSE TO TREATMENT WITHIN THE PROSPECTIVE GMMG MM5 PHASE III TRIAL. Haematologica, 103. S. 11 - 13. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Piechotta, V, John, L., Jung, J., Graziani, G., Reinhardt, H., Holtick, U., Semrau, R., Trog, D., Voelker, L. A., Herling, M., Fend, F., Harder, L., Weinhold, N., Kriegsmann, K., Merz, M., Delorme, S., Derlin, T., Raab, M. S., Goede, V, Schubert, M., Hohloch, K., Senf, B., Simon, S. T., Baumann, W., Fetscher, S., Schinke, M., Holtkamp, U., Einsele, H., Engelhardt, M., Goldschmidt, H., Scheid, C. and Skoetz, N. (2020). Interdisciplinary guideline on diagnosis, therapy, and follow-up of adult patients with monoclonal gammopathy of undetermined significance or multiple myeloma. Oncol. Res. Treat., 43 (SUPPL 4). S. 96 - 97. BASEL: KARGER. ISSN 2296-5262
Scheid, C., Engelhardt, M., Goldschmidt, H., Einsele, H., Starbatty, B., Bischoff, M., Glossmann, J-P and Skoetz, N. (2016). Standard Operating Procedures (SOPs) of centers of excellence for the diagnosis, treatment and follow-up of multiple myeloma patients: similarities and differences. Oncol. Res. Treat., 39. S. 68 - 69. BASEL: KARGER. ISSN 2296-5262
Scheid, C., Hose, D., Bertsch, U., Hielscher, T., Kunz, C., Salwender, H., Haenel, M., Merz, M., Mai, E. K., Schurich, B., Munder, M., Schmidt-Wolf, I, Gerecke, C., Lindemann, W., Zeis, M., Weisel, K., Duerig, J., Jauch, A., Peters-Regehr, T., Zorn, M. and Goldschmidt, H. (2015). Comparative assessment of myeloma response to induction treatment in the GMMG MM5 study using IMWG criteria and hevylite assay. Oncol. Res. Treat., 38. S. 10 - 11. BASEL: KARGER. ISSN 2296-5262
Scheid, C., Roellig, C., Weisel, K., Salwender, H-J, Gramatzki, M., Edmaier-Schroeger, K., Sy, O. and Goldschmidt, H. (2018). Durable progression-free survival benefit in early responders to elotuzumab plus lenalidomide and dexamethasone (ELd): analysis of ELOQUENT-2 4-year data in relapsed/refractory (RR) multiple myeloma (MM). Oncol. Res. Treat., 41. S. 189 - 190. BASEL: KARGER. ISSN 2296-5262
Schmidt-Wolf, I. G. H., Straka, C., Scheid, C., Einsele, H., Goldschmidt, H. and Engelhardt, M. (2014). State of the art treatment of progressive or refractory multiple myeloma. Dtsch. Med. Wochenschr., 139 (41). S. 2091 - 2096. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-4413
Stroh, J., Seckinger, A., Heider, M., Eichner, R., Schick, M., Slawska, J., Emde, M., Salwender, H., Bertsch, U., Goldschmidt, H., Weisel, K., Scheid, C., Keller, U., Hose, D. and Bassermann, F. (2020). MCT1 as molecularly validated predictive marker for lenalidomide-maintenance therapy in multiple myeloma. Oncol. Res. Treat., 43 (SUPPL 4). S. 95 - 96. BASEL: KARGER. ISSN 2296-5262
Weisel, K., Salwender, H., Scheid, C., Zago, M., Besemer, B., Haenel, M., Duerig, J., Munder, M., Lindemann, H. -W, Seckinger, A., Kunz, C., Benner, A., Hose, D., Jauch, A., Kanz, L. and Goldschmidt, H. (2018). Pomalidomide, cyclophosphamide and dexamethasone in case of suboptimal response to pomalidomide and dexamethasone alone in relapsed and/or refractory multiple myeloma: Final results of the GMMG-PERSPECTIVE trial. Oncol. Res. Treat., 41. S. 133 - 135. BASEL: KARGER. ISSN 2296-5262